|
29 Companies |
|
28 Products |
|
28 Products |
|
27 Mechanisms of Action |
|
0 Trials |
|
447 News |
|
| «12345678910» |
- Trial primary completion date: Microdermabrasion for Acne (clinicaltrials.gov) - Jul 10, 2015
P2, N=24, Completed, Sponsor: University of Michigan
Trial primary completion date: Jan 2008 --> Jul 2007
- || adapalene/benzoyl peroxide / Generic mfg.
Trial primary completion date: PUMP-it: Application of Epiduo(R) PUMP in Daily Practice in Patients With Inflammatory Acne (clinicaltrials.gov) - Jun 30, 2015
P=N/A, N=2000, Enrolling by invitation, Sponsor: Galderma Laboratorium GmbH
Trial primary completion date: Jan 2008 --> Jul 2007 Trial primary completion date: Jun 2015 --> Sep 2015
- || Enrollment closed, Trial primary completion date: Drug Utilization Study on Diane-35 (and Generics) in Three European Healthcare Databases (clinicaltrials.gov) - Jun 29, 2015
P=N/A, N=10000, Active, not recruiting, Sponsor: Bayer
Trial primary completion date: Jun 2015 --> Sep 2015 Not yet recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Dec 2015
- |||||||||| benzoyl peroxide/clindamycin / Generic mfg., clindamycin phosphate / Generic mfg.
New P3 trial: To Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris. (clinicaltrials.gov) - Jun 8, 2015
P3, N=1100, Recruiting, Sponsor: Glenmark Pharmaceuticals Ltd. India
- Enrollment open: Risk Minimisation Study for Diane-35 and Its Generics (clinicaltrials.gov) - Jun 4, 2015
P=N/A, N=1, Recruiting, Sponsor: Bayer
Not yet recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Dec 2015 Not yet recruiting --> Recruiting
- || Erbitux (cetuximab) / Eli Lilly
Enrollment closed: Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab (clinicaltrials.gov) - May 12, 2015
P=N/A, N=100, Active, not recruiting, Sponsor: Rambam Health Care Campus
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting
- ||| Trial completion: Study to Investigate the Irritation Potential of GSK1940029 Gel (clinicaltrials.gov) - May 12, 2015
P1, N=54, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Active, not recruiting Recruiting --> Completed
- Trial initiation date: Risk Minimisation Study for Diane-35 and Its Generics (clinicaltrials.gov) - May 6, 2015
P=N/A, N=1, Not yet recruiting, Sponsor: Bayer
Recruiting --> Completed Initiation date: Oct 2015 --> May 2015
- | NN1213 / Novo Nordisk
Trial completion: Infrared Non-Cutting Laser Therapy for Acne (clinicaltrials.gov) - May 2, 2015
P2/3, N=50, Completed, Sponsor: University of Michigan
Initiation date: Oct 2015 --> May 2015 Recruiting --> Completed
- Enrollment change: Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix (clinicaltrials.gov) - May 1, 2015
P1/2, N=33, Completed, Sponsor: University of Michigan
Recruiting --> Completed N=50 --> 33
- Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Phase classification, Enrollment change: Safety and Efficacy of the Use of Botox on Acne (clinicaltrials.gov) - Apr 30, 2015
P2, N=5, Terminated, Sponsor: DeNova Research
N=50 --> 33 Phase classification: P3 --> P2 | N=20 --> 5
- ||| tazarotene topical / Generic mfg.
Trial completion: Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris (clinicaltrials.gov) - Apr 30, 2015
P1, N=78, Completed, Sponsor: Allergan
Phase classification: P3 --> P2 | N=20 --> 5 Active, not recruiting --> Completed
- Enrollment open: Impact of the M22-IPL Acne Filter on Acne Vulgaris (clinicaltrials.gov) - Apr 29, 2015
P=N/A, N=20, Recruiting, Sponsor: Lumenis Ltd.
Active, not recruiting --> Completed Withheld --> Recruiting
- | NN1213 / Novo Nordisk
Trial completion: Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix (clinicaltrials.gov) - Apr 29, 2015
P1/2, N=33, Completed, Sponsor: University of Michigan
Withheld --> Recruiting Recruiting --> Completed
- ||||| Seysara (sarecycline) / Paratek, Almirall
Enrollment closed: A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris (clinicaltrials.gov) - Apr 28, 2015
P3, N=500, Active, not recruiting, Sponsor: Warner Chilcott
Recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- Enrollment closed: A Study to Evaluate the Clinical Effect of Daily Next Science (clinicaltrials.gov) - Apr 28, 2015
P1/2, N=72, Active, not recruiting, Sponsor: Next Science TM
Enrolling by invitation --> Active, not recruiting Recruiting --> Active, not recruiting
- acebilustat (CTX-4430) / Celtaxsys
Enrollment open: CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris (clinicaltrials.gov) - Apr 27, 2015
P2, N=156, Recruiting, Sponsor: Celtaxsys, Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- isotretinoin / Generic mfg., adapalene / Generic mfg.
Enrollment closed, Trial primary completion date: The Lipid Profile of the Skin Surface in Acne (clinicaltrials.gov) - Apr 22, 2015
P=N/A, N=45, Active, not recruiting, Sponsor: University of California, Davis
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> May 2015
- ||| Trial completion, Trial primary completion date: Study to Evaluate the Safety, Tolerability and Pharmacokinetic of Single and 14 Day Repeat Topical Application of GSK1940029 (clinicaltrials.gov) - Apr 22, 2015
P1, N=55, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> May 2015 Recruiting --> Completed | Trial primary completion date: Oct 2014 --> Feb 2015
- || Trial primary completion date: Study to Investigate the Irritation Potential of GSK1940029 Gel (clinicaltrials.gov) - Apr 19, 2015
P1, N=71, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Completed | Trial primary completion date: Oct 2014 --> Feb 2015 Trial primary completion date: Oct 2014 --> Sep 2015
- | MTC 896 / Mimetica
Trial completion, Enrollment change: Pharmacokinetic Study of MTC896 Gel in Subjects With Acne (clinicaltrials.gov) - Apr 17, 2015
P1/2, N=32, Completed, Sponsor: Mimetica Pty Limited
Trial primary completion date: Oct 2014 --> Sep 2015 Recruiting --> Completed | N=45 --> 32
- Trial primary completion date: Potential Research Study Participant Registry (clinicaltrials.gov) - Apr 16, 2015
P=N/A, N=200, Recruiting, Sponsor: University of California, Davis
Recruiting --> Completed | N=45 --> 32 Trial primary completion date: Jan 2015 --> Jan 2025
- |||||||||| Seysara (sarecycline) / Paratek, Almirall
New P3 trial: A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris (clinicaltrials.gov) - Apr 9, 2015
P3, N=500, Enrolling by invitation, Sponsor: Warner Chilcott
- ||| adapalene / Generic mfg.
New P1 trial: Study Comparing Adapalene Gel 0.3% to Differin (clinicaltrials.gov) - Apr 8, 2015
P1, N=753, Completed, Sponsor: Taro Pharmaceuticals USA
- ||| tazarotene topical / Generic mfg.
New P1 trial: A Study Comparing Tazarotene Cream 0.1% to Tazorac (clinicaltrials.gov) - Apr 8, 2015
P1, N=1077, Completed, Sponsor: Taro Pharmaceuticals USA
- New trial: Risk Minimisation Study for Diane-35 and Its Generics (clinicaltrials.gov) - Apr 7, 2015
P=N/A, N=1, Not yet recruiting, Sponsor: Bayer
- | berdazimer sodium (SB204) / Sato Pharma, Novan
Trial completion: A 2 Period Cross-over Pharmacokinetic Study of SB204 in Acne Vulgaris (clinicaltrials.gov) - Apr 3, 2015
P1, N=18, Completed, Sponsor: Novan, Inc.
Trial primary completion date: Jan 2015 --> Jan 2025 Active, not recruiting --> Completed
- Enrollment closed: Pivotal Study of Sebacia Microparticles in the Treatment of Acne Vulgaris (clinicaltrials.gov) - Apr 2, 2015
P=N/A, N=300, Active, not recruiting, Sponsor: Sebacia, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | New P1/2 trial: A Study to Evaluate the Clinical Effect of Daily Next Science (clinicaltrials.gov) - Mar 31, 2015
P1/2, N=72, Recruiting, Sponsor: Next Science TM
- ||| berdazimer sodium (SB204) / Sato Pharma, Novan
Enrollment closed: P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris (clinicaltrials.gov) - Mar 31, 2015
P2, N=200, Active, not recruiting, Sponsor: Novan, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Clinical: Clinical Effect of Platelet Rich Plasma Combined With Laser on Scar (clinicaltrials.gov) - Mar 26, 2015
P=N/A, N=29, Completed, Sponsor: Seoul National University Hospital
- | Trial completion: Topical PDT Cream Without Irradiation Source in the Acne Treatment (clinicaltrials.gov) - Mar 17, 2015
P=N/A, N=45, Completed, Sponsor: Seoul National University Hospital
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| adapalene/benzoyl peroxide / Generic mfg.
Trial completion: Dermatologists' Educational Demonstration for Epiduo Application (clinicaltrials.gov) - Mar 17, 2015
P=N/A, N=85, Completed, Sponsor: Seoul National University Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| dapsone / Generic mfg.
Trial completion: A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris (clinicaltrials.gov) - Mar 14, 2015
P4, N=67, Completed, Sponsor: Allergan
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | acebilustat (CTX-4430) / Celtaxsys
New P2 trial: CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris (clinicaltrials.gov) - Mar 12, 2015
P2, N=156, Not yet recruiting, Sponsor: Celtaxsys, Inc.
- || tazarotene topical / Generic mfg.
Enrollment closed: Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris (clinicaltrials.gov) - Feb 27, 2015
P1, N=78, Active, not recruiting, Sponsor: Allergan
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- dapsone / Generic mfg.
Trial completion: Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel (clinicaltrials.gov) - Feb 27, 2015
P4, N=32, Completed, Sponsor: Derm Research, PLLC
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Pliaglis (lidocaine and tetracaine topical cream 7%/7%) / Galderma
New P4 trial: OPTICA: 7% Lidocaine/7% Tetracaine Cream Versus 2,5% Lidocaine / 2,5% Prilocaine Cream (clinicaltrials.gov) - Feb 26, 2015
P4, N=30, Recruiting, Sponsor: Erasmus Medical Center
- isotretinoin / Generic mfg.
Enrollment change, Trial termination: Musculoskeletal Effects of Isotretinoin During Acne Treatment in Pediatric Population (clinicaltrials.gov) - Feb 23, 2015
P=N/A, N=15, Terminated, Sponsor: University of Wisconsin, Madison
Active, not recruiting --> Completed N=65 --> 15 | Active, not recruiting --> Terminated; Principal Investigator has left Sponsoring Instiution
- azelaic acid gel / Generic mfg.
Enrollment closed, Trial primary completion date: Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study (clinicaltrials.gov) - Feb 19, 2015
P4, N=20, Active, not recruiting, Sponsor: Derm Research, PLLC
N=65 --> 15 | Active, not recruiting --> Terminated; Principal Investigator has left Sponsoring Instiution Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Mar 2015
- | Stelara (ustekinumab) / J&J
Trial completion: A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa (clinicaltrials.gov) - Feb 13, 2015
P2, N=20, Completed, Sponsor: University Medical Centre Groningen
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Mar 2015 Active, not recruiting --> Completed
- Enrollment change: UVA1 Light for Scleroderma and Similar Conditions (clinicaltrials.gov) - Feb 11, 2015
P=N/A, N=23, Terminated, Sponsor: University of Michigan
Active, not recruiting --> Completed N=50 --> 23
- | isotretinoin / Generic mfg.
Trial completion: Proof of Concept Study to Investigate the Recurrence of Acne Post Isotretinoin (clinicaltrials.gov) - Feb 10, 2015
P4, N=20, Completed, Sponsor: Dermatrials Research
N=50 --> 23 Active, not recruiting --> Completed
- |||| Humira (adalimumab) / AbbVie
Trial primary completion date: PIONEER (OLE): Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa (clinicaltrials.gov) - Feb 2, 2015
P3, N=540, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Trial primary completion date: Jan 2015 --> Jul 2015
- ||| Enrollment change: BLI1100-202: BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris (clinicaltrials.gov) - Feb 2, 2015
P2, N=369, Completed, Sponsor: Braintree Laboratories
Trial primary completion date: Jan 2015 --> Jul 2015 N=300 --> 369
- Enrollment closed, Combination therapy: Microneedling Plus the Universal Peel For Acne Scarring (clinicaltrials.gov) - Feb 2, 2015
P=N/A, N=15, Active, not recruiting, Sponsor: Englewood Hospital and Medical Center
N=300 --> 369 Recruiting --> Active, not recruiting
- Trial completion, Trial primary completion date: Pilot Study to Evaluate Tea Tree Oil Gel for Facial Acne (clinicaltrials.gov) - Jan 28, 2015
P2, N=18, Completed, Sponsor: The University of Western Australia
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Dec 2014
- ||| adapalene/benzoyl peroxide / Generic mfg.
Clinical: PUMP-it: Application of Epiduo(R) PUMP in Daily Practice in Patients With Inflammatory Acne (clinicaltrials.gov) - Jan 15, 2015
P=N/A, N=2000, Enrolling by invitation, Sponsor: Galderma Laboratorium GmbH
- ||| adapalene/benzoyl peroxide / Generic mfg.
Trial completion: ELANG: Long-term Study of Epiduo in Patients With Moderate to Severe Acne (clinicaltrials.gov) - Jan 13, 2015
P=N/A, N=6036, Completed, Sponsor: Galderma Laboratorium GmbH
Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Dec 2014 Enrolling by invitation --> Completed
- | Enrollment open: Effects of Omega-3 Fatty Acid Supplementation in Acne Patients (clinicaltrials.gov) - Jan 9, 2015
P3, N=90, Recruiting, Sponsor: University of California, Los Angeles
Enrolling by invitation --> Completed Active, not recruiting --> Recruiting